Complexes of Amphotericin B and Cholesteryl Sulfate

References

• Walsh T. J., Pizzo A. Treatment of systemic fungal infections: recent progress and current problems. Eur. J. Clin. Microbiol. Infect. Dis. 1988; 7: 460–475
   PubMed Web of Science ®Google Scholar
• Lopez-Berestein G., Fainstein V., Hopfer R., Mehta K., Sullivan M. P., Keating M., Rosenblum M. G., Mehta R., Luna M., Hersh E. M., Reuben J., Juliano R. L., Bodey G. P. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: A preliminary study. J. Infect. Dis. 1985; 151: 704–710
   PubMed Web of Science ®Google Scholar
• Lopez-Berestein G., Bodey G. P., Frankel L. S., Mehta K. Treatment of heptosplenic candidiasis with liposomal amphotericin B. J. Clin. Oncol. 1987; 5: 310–317
   PubMed Web of Science ®Google Scholar
• Lopez-Berestein G., Bodey G. P., Fainstein V., Keating M., Frankel L. S., Zeluff B., Gentry L., Mehta K. Treatment of systemic fungal infections with liposomal amphotericin B. Arch. Intern. Med. 1989; 149: 2533–2536
   PubMed Web of Science ®Google Scholar
• Moser H. W., Moser A. B., Orr J. C. Preliminary observations on the occurence of cholesterol sulfate in man. Biochim. Biophys. Acta 1966; 116: 146–155
   PubMed Web of Science ®Google Scholar
• Hochberg R. B., Ladany S., Lieberman S. Cholesteryl sulfate: Some aspects if its biosynthesis and uptake by tissues by blood. Endocrinology 1966; 94: 207–213
   Google Scholar
• Guo L. S. S., Fielding R. M., Lasic D. D., Hamilton R. L., Mufson D. Novel antifungal drug delivery: stable amphotericin B-cholesteryl sulfate discs. Int. J. Pharmaceu. 1991; 75: 45–54
   Web of Science ®Google Scholar
• Guo L. S. S., Fielding R. M., Gantz D. L., Steiner J., Small D. M. Structure of amphotericin B colloidal disperision (ABCD): A novel amphotericin B dosage form. 31st Intersci. Conf. Antimicrob. Agents Chemother. 1991; 135, Abstr. 221
   Google Scholar
• Hanson L. H., Stevens D. A. Comparison of antifungal activity of amphotericin B deoxycholate suspension with that of amphotericin B cholesteryl sulfate colloidal dispersion. Antimicrob. Agents Chemother. 1992; 36: 486–488
   PubMed Web of Science ®Google Scholar
• Clemons K. V., Stevens D. A. Comparative efficicy of amphotericin B colloidal dispersion and amphotericin B dexoycholate suspension in treatment of murine coccidioidomycosis. Antimicrob. Agents Chemother. 1991; 35: 1829–1833
   PubMed Web of Science ®Google Scholar
• Hostetler J. S., Clemons K. V., Hanson L. H., Stevens D. A. Efficacy and safety of amphotericin B colloidal dispersion comnpared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis. Antimicrob. Agents Chemother. 1992; 36: 2656–2660
   PubMed Web of Science ®Google Scholar
• Allende M., Francis P., Berenguer J., Lee J., Garrett K., Dollenberg H., Pizzo P., Walsh T. Efficacy of amphotericin B colloidal dispersion (ABCD) in the treatment of invasive pulmonary aspergillosis in rabbits. The 32nd Intersci. Conf. Antimicrob. Agents Chemother. 1992; 140, abstr. 180
   Google Scholar
• Wang L. H., Smith P. C., Anderson K. L., Fielding R. M. High-performance liquid chromatographic analysis of amphotericin B in plasma, blood, urine and tdissues for pharmacokinetic and tissue distribution studies. J. Chromatogr. 1992; 579: 259–268
   PubMed Web of Science ®Google Scholar
• Fielding R. M., Smith P. C., Wang L. H., Porter J., Guo L. S. S. Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation in the rat. Antimicrob. Agents Chemother. 1991; 35: 1208–1211
   PubMed Web of Science ®Google Scholar
• Fielding R. M., Singer A. W., Wang L. H., Babbar S., Guo L. S. S. Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs. Antimicrob. Agents Chemother. 1992; 36: 299–307
   PubMed Web of Science ®Google Scholar
• Lasser A. The mononuclear phagocytosystem: A review. Human Pathol. 1983; 14: 108–129
   PubMed Web of Science ®Google Scholar
• Lawrence R. M., Hoeprich P. D., Jagids F. A., Monji N., Huston A. C., Schaffner C. P. Distribution of doubly labeled amphotericin B methyl ester and amphotericin B in the non-human primate, Macaca mulatta. J. Antimicrob. Chemother. 1980; 6: 241–249
   PubMed Web of Science ®Google Scholar
• Christiansen K. L., Bernard E. M., Gold J. W. M., Armstrong D. Distribution and activity of amphotericin B in children. J. Infect. Dis. 1985; 152: 1037–1043
   PubMed Web of Science ®Google Scholar
• Sanders S. W., Buchi K. N., Goddard M. S., Lang J. K., Tolman K. G. Single-dose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to healthy volunteers. Antimicrob. Agents Chemother. 1991; 35: 1029–1034
   PubMed Web of Science ®Google Scholar
• Craven P. C., Ludden T. H., Drutz D. J., Rogers W., Haegele K. S., Skrdlant H. B. Excretion pathways for amphotericin B. J. Infect. Dis. 1979; 140: 329–341
   PubMed Web of Science ®Google Scholar
• Atkinson A. J., Jr., Bennett J. E. Amphotericin B pharmacokinetics in humans. Antimicrob. Agents Chemother. 1978; 13: 271–276
   PubMed Web of Science ®Google Scholar
• Sande M. A., Mandell G. L. Antifungal and antiviral agents. “The pharmacological basis of therpeutics”, A. G. Gilman, L. S. Goodman, T. W. Rall, F. Murad. Macmillan, New York 1985; 1219–1222
   Google Scholar
• Benson J. M., Nahata M. C. Pharmacokinetics of amphotericin B in children. Antimicrob. Agents Chemother. 1989; 13: 271–276
   Google Scholar
• Chabot G. G., Pazdur R., Valeriote F. A., Baker L. H. Pharmacokinetics and toxicity of continuous infusion amphotericin B in cancer patients. J. Pharm. Sci. 1989; 78: 307–310
   PubMed Web of Science ®Google Scholar
• Bowden R., Cays M. Phase I study of amphotericin B colloidal dispersion (ABCD) for the treatment of invasive fungal infection after marrow transplant. The 32 Intersci. Conf. Antimicrob. Agents Chemother. 1992; 214, Abstr. 621
   Google Scholar